BG
ASND icon

Bollard Group’s Ascendis Pharma A/S ASND Stock Holding History

Bollard Group’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-15,400
Closed -$1.81M – 296
2022
Q1 		$1.81M Buy
+15,400
New +$1.78M 0.06% 117

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Bollard Group's ASND Position: Q2 2022 in Review

Bollard Group sold out of Ascendis Pharma A/S (ASND) in Q2 2022, closing a stake of 15,400 shares — an estimated $1.81M sold.

Bollard Group first reported a position in ASND in Q1 2022 and held it in 1 quarter. The position peaked at $1.81M in Q1 2022. 168 funds tracked by Wall St. Rank hold ASND as of Q2 2022.

  • Bollard Group reported no remaining Ascendis Pharma A/S position as of Q2 2022 after selling out during the quarter.
  • Bollard Group sold 15,400 Ascendis Pharma A/S shares in Q2 2022, an estimated $1.81M.
  • Bollard Group first reported a position in Ascendis Pharma A/S in Q1 2022 and held it in 1 quarter.
  • Bollard Group's Ascendis Pharma A/S position peaked at $1.81M in Q1 2022.
  • 168 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2022.

Based on Bollard Group's 13F filing for Q2 2022, filed 12 Aug 2022.